Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Home
Search
Quick Search
Advanced
Fulltext
Browse
Collections
Persons
My eDoc
Session History
Login
Name:
Password:
Documentation
Help
Support Wiki
Direct access to
document ID:


          Institute: MPI für medizinische Forschung     Collection: jahrbuch_2011_archival     Display Documents



ID: 597783.0, MPI für medizinische Forschung / jahrbuch_2011_archival
The bacterial redox signaller pyocyanin as an antiplasmodial agent: comparisons with its thioanalog methylene blue
Translation of Title:The bacterial redox signaller pyocyanin as an antiplasmodial agent: comparisons with its thioanalog methylene blue
Authors:Kasozi, D. M.; Gromer, S.; Adler, Heike; Zocher, K.; Rahlfs, Stefan; Wittlin, Sergio; Fritz−Wolf, Karin; Schirmer, R. Heiner; Becker, Katja
Language:English
Date of Publication (YYYY-MM-DD):2011-07-01
Title of Journal:Redox Report
Journal Abbrev.:Redox Report
Volume:16
Issue / Number:4
Start Page:154
End Page:165
Review Status:Peer-review
Audience:Experts Only
Intended Educational Use:No
Abstract / Description:The quorum sensor and signalling molecule pyocyanin (PYO) contributes significantly to the pathophysiology of Pseudomonas aeruginosa infections. Comparison to phenothiazine drugs suggests that the antimalarial compound methylene blue (MB) can be regarded as a sulfur analog of PYO. This working hypothesis would explain why the synthetic drug MB behaves as a compound shaped in biological evolution. Here we report on redox−associated biological and biochemical properties of PYO in direct comparison to its synthetic analog MB. We quantitatively describe the reactivity of both compounds toward cellular reductants, the reactivity of their reduced leuco−forms towards O2, and their interactions with FAD−containing disulfide reductases. Furthermore, the interaction of PYO with human glutathione reductase was studied in structural detail by x−ray crystallography, showing that a single PYO molecule binds to the intersubunit cavity of the enzyme. Like MB, also PYO was also found to be active against blood schizonts of the malaria parasite P. falciparum in vitro. Furthermore, both compounds were active against the disease transmitting gametocyte forms of the parasites, which was systematically studied in vitro. As shown for mice, PYO is too toxic to be used as a drug. It may, however, have antimalarial activity in numerous human patients with concomitant Pseudomonas infections. MB, in contrast to PYO, is well tolerated and represents a promising agent for MB−based combination therapies against malaria. Current and future clinical studies can be guided by the comparisons between MB and PYO reported here. Additionally, it is of interest to study if and to what extent the protection from malaria in patients with cystic fibrosis or with severe wound infections is based on PYO produced by Pseudomonas species
Free Keywords:Diaphorase; Stage−specific drug effects; Enzyme inhibition; Wound infections; Plasmodium falciparum; Toxicology; Redox−cycling drugs; Gametocyticidal drugs
External Publication Status:published
Document Type:Article
Communicated by:Wulf Kaiser
Affiliations:MPI für medizinische Forschung/Abteilung Biophysik
MPI für medizinische Forschung/Abteilung Biomolekulare Mechanismen
Identifiers:LOCALID:7696
URI:http%3A%2F%2Fwww.ingentaconnect.com%2Fcontent%2Fma...
DOI:10.1179%2F174329211X13049558293678
Full Text:
Sorry, no privileges
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.